Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Blood(2020)10.1182/blood.2020006288Source: DataRank Database

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients is a research paper published in Blood (2020). On theSindex it has a DataRank of 0.875. It has been cited 341 times.

N/A

0.875DataRank · unranked

Scored on demand from live citation data

Open Access341 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 34.72)OA: bronzeTopics (78)Linked Datasets (8)DataCite Reuse (8)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.875

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (8)

Jorge J. Castillo ORCID,Alan P Skarbnik ORCID,Jacob D. Soumerai ORCID,Irene M. Ghobrial ORCID,Maria Luisa Guerrera ORCID

Live enrichment

PubMed:32302379 PMC:PMC7243149 OpenAlex:https://openalex.org/W3016852213

NCI NIH HHS

Grant: P50 CA100707

National Institutes of Health

Grant: 5P50CA100707-03

Specialized Program of Research Excellence in Myeloma

FWCI

34.72

Citation Percentile

1.0%

Citation Trend

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

bronze

journalhttps://ashpublications.org/blood/article-pdf/135/21/1912/1800674/bloodbld2020006288.pdf

publisherhttps://ashpublications.org/blood/article-pdf/135/21/1912/1800674/bloodbld2020006288.pdf

publisherhttp://ashpublications.org/blood/article-pdf/135/21/1912/1800674/bloodbld2020006288.pdf

journalhttps://doi.org/10.1182/blood.2020006288

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32302379

Fields of Study

Chronic Lymphocytic Leukemia ResearchGalectins and Cancer BiologyPI3K/AKT/mTOR signaling in cancer0301 basic medicine03 medical and health sciences0302 clinical medicineAdenineAgammaglobulinaemia Tyrosine KinaseAgedBetacoronavirusCOVID-19Coronavirus InfectionsFemaleHumansLung InjuryMaleMiddle AgedPandemicsPiperidinesPneumonia, ViralProtein Kinase InhibitorsPyrazolesPyrimidinesSARS-CoV-2Waldenstrom Macroglobulinemia

MeSH Terms

BetacoronavirusAgammaglobulinaemia Tyrosine KinaseCOVID-19SARS-CoV-2AdenineAgedFemaleHumansWaldenstrom MacroglobulinemiaMaleMiddle AgedPiperidinesPneumonia, ViralPyrazolesPyrimidinesCoronavirus InfectionsProtein Kinase InhibitorsLung InjuryPandemics

Keywords

IbrutinibBruton's tyrosine kinaseCoronavirus disease 2019 (COVID-19)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyInternal medicineIntensive care medicineLeukemiaChronic lymphocytic leukemiaInfectious disease (medical specialty)ReceptorDiseaseTyrosine kinaseMaleSARS-CoV-2AdeninePneumonia, ViralCOVID-19Lung InjuryMiddle AgedBetacoronavirusPyrimidinesPiperidinesAgammaglobulinaemia Tyrosine KinaseHumansPyrazolesFemaleWaldenstrom MacroglobulinemiaLetter to BloodCoronavirus InfectionsPandemicsProtein Kinase InhibitorsAged

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 2 of The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR

10.6084/m9.figshare.12972100.v1figshare

Additional file 2 of The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR

10.6084/m9.figshare.12972100figshare

Additional file 1 of Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

10.6084/m9.figshare.14432942.v1figshare

Additional file 1 of Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

10.6084/m9.figshare.14432942figshare

Additional file 1 of The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR

10.6084/m9.figshare.12972097.v1figshare

Additional file 3 of The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR

10.6084/m9.figshare.12972103.v1figshare

Additional file 3 of The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR

10.6084/m9.figshare.12972103figshare

Additional file 1 of The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR

10.6084/m9.figshare.12972097figshare

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

FAIR Checklist

DataRank Breakdown

Authors (8)

Funding (2 grants)

Impact

Open Access

Topics

Linked Datasets (8)

Annotations (Europe PMC)